{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.4","upperLimit":"68.8","value":"46.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"}],"units":"Participants"}],"description":"Response was assessed using IMWG guidelines, which for progressive disease are as follows:\n\nIncrease of \\> 25% from lowest response value in any one or more of the following:\n\n* Serum M-component and/or (the absolute increase must be \\> 0.5 g/dL)\\*\n* Urine M-component and/or (the absolute increase must be \\> 200 mg/24 h)\n* Only in patients without measurable serum and urine M-protein levels; the difference between involved and uninvolved FLC levels. The absolute increase must be \\> 10 mg/dL\n* Bone marrow plasma cell percentage; the absolute percentage must be \\> 10%\n* Definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas\n* Development of hypercalcaemia (corrected serum calcium \\> 11.5 mg/dL or 2.65 mmol/L) that can be attributed solely to the plasma cell proliferative disorder IF starting M protein component is \\> 5g/dL, then absolute increase of 1g is sufficient for progression.","dispersionType":"Full Range","groups":[{"description":"Bortezomib, Dexamethasone, Pegylated Liposomal Doxorubicin, Cyclophosphamide: Bortezomib 1.3 mg/m2 days 1, 4, 8, 11 (initial cycles) Dexamethasone 40 mg Days 1-4, 8-11, 15-18 (initial cycles) Doxil 30 mg/m2 Day 4 of subsequent cycles","id":"OG000","title":"Treatment Arm (All Patients)"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Date of progression, assessed from start of trial to Final data cut off date (15 April 2011)","title":"Progression Free Survival","type":"SECONDARY","unitOfMeasure":"months"}